For additional information please call the Oncology Service at (608) 890-0422 or email at oncclinicaltrials@vetmed.wisc.edu
NEW 5/15/26 – Looking for dogs with AGASACA
Our team is looking for dogs diagnosed with apocrine gland anal sac adenocarcinomas to determine the utility of PET/CT for identifying cancer spread.
They need to enroll in the study BEFORE they have surgery, chemotherapy, or radiation therapy.
Dogs enrolled with receive a free PET/CT scan before starting treatment. Clients are responsible for the cost of the initial diagnosis. Dogs will need to be dropped off at UW Veterinary Care for 1 day to have the scan.
To enroll please email clinicalstudies@vetmed.wisc.edu or call 608-890-3484 if questions.
NEW 5/15/26 – Looking for Dogs with Nasal Masses
Researchers at the UW Veterinary care and School of Public Health are validating a blood-based cancer detection test (CancerK9) to distinguish canine nasal tumors from rhinitis caused by infection or inflammation.
Your dog will receive a free CancerK9 blood test and interpretation and free histopathology on samples collected from nasal lesions ($200 value). Physical exams, anesthesia and sampling required are not covered by the study.
If your dog has a nasal mass, please contact UW Veterinary Care at 608-263-7600 to schedule an appointment. If you have questions about the study, please contact cancerbt@vetmed.wisc.edu.
Cancer screening Blood Test for Any Dog Over 20#
We are offering a free cancer screening test for any dog over 20#. They don’t need to be previous patients at UW Veterinary Care.
The CancerK9 test is a screening tool that measure DNA fragments in the blood. The results are sent to your regular veterinarian who may call or email to consult with the team to help interpret the results which take 2-3 weeks. There are 3 result types:
1. No evidence of cancer
2. ”Gray area” – may be cancer, but more often infectious or inflammatory conditions (Ex: chronic allergies, ear infections, UTI’s, or persistent Lyme antibodies), recommend retesting 3-6 months after treatment
3. Cancer likely – recommend follow up with your regular vet to get samples of any known masses, a chest x-ray, and abdominal ultrasound to look for internal signs of cancer.
If interested in scheduling, please email clinicalstudies@vetmed.wisc.edu.
NEW – Targeted Radiopharmaceutical Therapy (RPT) in Companion Dogs with Peripheral T-Cell Lymphoma (PTCL)
- Dogs with flow cytometric or immunohistochemical (IHC)-confirmed PTCL (any stage, as long as the tumor can be sampled).
- Must have a measurable lesion accessible to biopsy.
- Patient older than one (1) year of age.
- ≥ 10 kg body weight.
- Signed owner informed consent.
- Dogs with VCOG-CTCAE constitutional signs ≤ 1
- Dogs without flow cytometric or IHC-confirmed PTCL.
- Dogs without a measurable tumor accessible for biopsy.
- Dogs younger than one year.
- Dogs weighing less than 10 kg.
- Pregnant or lactating dogs.
- Dogs with VCOG-CTCAE constitutional signs > 1.
-
Dogs with significant comorbidities that make it unlikely they can complete the trial
For additional information please call the Oncology Service at (608) 890-0422 or email at oncclinicaltrials@vetmed.wisc.edu.
FLASH Radiotherapy for Canine Osteosarcoma
FLASH radiation is defined as ultra-high dose rate radiation which has been shown in small animal and tissue models to spare normal tissues to a greater extent than normal radiation.
Any dog with suspect osteosarcoma on a limb will qualify.
1 treatment of radiation will be performed. Then your dog will be randomized to the FLASH group or the conventional radiation group for treatments. They will have 4 once/week follow up visits. If amputation is elected, it will be performed 1 month after the start of the study and the cost is covered by the study.
For more information, contact Dr. Tricia Hu at tghu@wisc.edu or Dr. Nathaniel Van Asselt at nvanasselt@wisc.edu or call 608-890-0422.
Visbiome Vs Metronidazole for diarrhea in dogs with lymphoma on CHOP
Vis vs Metro Flyer 25
The UWVC Oncology service is evaluating the efficacy of a probiotic (Visbiome Vet®), compared to traditionally used metronidazole for the management of chemotherapy induced diarrhea in dogs with multicentric lymphoma receiving a 19-week CHOP chemotherapy protocol.Dogs with a confirmed diagnosis of multicentric lymphoma whose owners present to the UWVC oncology service for consultation and elect to treat their dog with 19-week CHOP protocol will be given the option to participate in the clinical trial. Dogs will be randomized into either the Visbiome® Vet or metronidazole treatment groups.
Owners of patients in both groups will be instructed to keep a diary once enrolled in the trial to monitor stool frequency, consistency, and schedule. Diet and medications will also be recorded; owners will be instructed to keep their dog’s diet consistent. Owners will start the respective diarrhea management medication once stools reach a fecal score of >4 (Fecal Scoring System, Nestle Purina PetCare Company, St. Louis, MO), or increased frequency or urgency from baseline is noted. The Fecal Scoring System will be provided for owners, and they will also be encouraged to take photos of their dogs’ eliminations. Stool samples will be collected at baseline/enrollment, prior to each doxorubicin administration, and 1 month after completion of chemotherapy. These samples will be analyzed in future research with consultation with the Gastrointestinal lab at Texas A&M University.
Owners will be financially responsible all costs associated with diagnosis of multicentric lymphoma and treatment with CHOP chemotherapy with the exception of recheck examination fees for timepoints associated with fecal sample collection, which will be covered by the study as client incentive. The cost of metronidazole or Visbiome® Vet (depending upon their randomized group) will be paid for by the study.
For further information or to enroll a potential patient, please contact oncclinicaltrials@vetmed.wisc.edu or call 608-890-0422.